Sugi Predict

Sugi Predict / Compounds / SCHEMBL1660034

SCHEMBL1660034

SCHEMBL1660034

COc1cc2c(cc1Cl)C(=O)CC2

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK10 P53779 9/20 0.48
▸ MAPK14 Q16539 4/20 0.47
▸ MAPK9 P45984 2/20 0.47
▸ MAPK8 P45983 1/20 0.47
▸ TUBB4A P04350 1/20 0.46
▸ TUBB P07437 1/20 0.46
▸ TUBA3C P0DPH7 1/20 0.46
▸ TUBA1B P68363 1/20 0.46
▸ TUBA4A P68366 1/20 0.46
▸ TUBB4B P68371 1/20 0.46
▸ TUBB3 Q13509 1/20 0.46
▸ TUBB2A Q13885 1/20 0.46
▸ TUBB8 Q3ZCM7 1/20 0.46
▸ TUBA3E Q6PEY2 1/20 0.46
▸ TUBA1A Q71U36 1/20 0.46
▸ TUBA1C Q9BQE3 1/20 0.46
▸ TUBB6 Q9BUF5 1/20 0.46
▸ TUBB2B Q9BVA1 1/20 0.46
▸ TUBB1 Q9H4B7 1/20 0.46
▸ MEN1 O00255 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31288649 1.00 MAPK10 (0.48) MAPK10MAPK14MAPK9MAPK8TUBB4A
SCHEMBL2494625 0.93 MAPK10 (0.47) MAPK10MAPK14MAPK9MAPK8TUBB4A
SCHEMBL24362546 0.90 MAPK10 (0.46) MAPK10MAPK14MAPK9MAPK8TUBB4A
SCHEMBL29420327 0.85 KMT2A (0.56) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29420326 0.85 KMT2A (0.56) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL354177 0.85 KMT2A (0.56) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL30448793 0.83 HSD17B1 (0.49) MAPK10TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL23114042 0.83 HSD17B1 (0.49) MAPK10TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL3949987 0.80 TUBB4A (0.47) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL2306816 0.80 HTR2A (0.51) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124453-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2024-04-18 — — US disclosed
US-11884664-B2 Protein tyrosine phosphatase inhibitors ARRAY BIOPHARMA INC. (US) 2024-01-30 — — US disclosed
US-11634417-B2 Protein tyrosine phosphatase inhibitors ARRAY BIOPHARMA INC. (US) 2023-04-25 — — US disclosed
US-20220251083-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2022-08-11 — — US disclosed
CN-113874363-A Protein tyrosine phosphatase inhibitors ARRAY生物制药公司 2021-12-31 — — CN disclosed
US-20200317665-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2020-10-08 — — US disclosed
EP-1827421-B1 ESTROGEN RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2017-09-27 — — EP disclosed
EP-1827421-B1 ESTROGEN RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2017-09-27 — — EP disclosed
EP-1943224-B1 ESTROGEN RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2011-07-27 — — EP disclosed
EP-1943224-B1 ESTROGEN RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2011-07-27 — — EP disclosed
US-7511152-B2 Estrogen receptor modulators MERCK & CO., INC. (US) 2009-03-31 — — US disclosed
US-7511152-B2 Estrogen receptor modulators MERCK & CO., INC. (US) 2009-03-31 — — US disclosed
US-7511152-B2 Estrogen receptor modulators MERCK & CO., INC. (US) 2009-03-31 — — US disclosed
EP-1943224-A2 ESTROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2008-07-16 — — EP disclosed
US-20070265318-A1 6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one; uterine fibroid disease, hot flashes, urogenital disorders, inflammation; improved metabolic profile MERCK SHARP & DOHME LLC 2007-11-15 — — US disclosed
US-20070265318-A1 6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one; uterine fibroid disease, hot flashes, urogenital disorders, inflammation; improved metabolic profile MERCK SHARP & DOHME LLC 2007-11-15 — — US disclosed
US-20070265318-A1 6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one; uterine fibroid disease, hot flashes, urogenital disorders, inflammation; improved metabolic profile MERCK SHARP & DOHME LLC 2007-11-15 — — US disclosed
EP-1827421-A2 ESTROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2007-09-05 — — EP disclosed
WO-2007089291-A2 ESTROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2007-08-09 — — WO disclosed
WO-2006062876-A2 ESTROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2006-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11884664-B2 Protein tyrosine phosphatase inhibitors PPM1A, PPM1F, PPP5C MAPK10 295/4885MAPK14 182/4885MAPK9 372/4885
US-20070265318-A1 6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one; uterine fibroid disease, hot flashes, urogenital disorders, inflammation; improved metabolic profile GPER1, ESRRA, HSD17B11 MAPK10 971/4885MAPK14 1325/4885MAPK9 1464/4885
US-20200317665-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS PPM1A, PPM1F, PPP5C MAPK10 295/4885MAPK14 182/4885MAPK9 372/4885
US-20240124453-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS PPM1A, PPM1F, PPP5C MAPK10 295/4885MAPK14 182/4885MAPK9 372/4885
US-11634417-B2 Protein tyrosine phosphatase inhibitors PPM1A, PPM1F, PPP5C MAPK10 295/4885MAPK14 182/4885MAPK9 372/4885
US-20220251083-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS PPM1A, PPM1F, PPP5C MAPK10 295/4885MAPK14 182/4885MAPK9 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.